Target intelligence / Profile preview

Multidrug resistance protein 1 (P-glycoprotein) (ABCB1)

Target
ABCB1
Molecular classification
Transporter, ATP-binding cassette transporter, ABCB family
01

Overview

Multidrug resistance protein 1 (ABCB1), widely known as P-glycoprotein (P-gp), is a member of the ATP-binding cassette (ABC) transporter superfamily that functions as a broad-spectrum efflux pump [1]. It is strategically expressed in barrier tissues such as the intestinal epithelium, the blood-brain barrier, and the canalicular membrane of hepatocytes, where it limits the absorption and enhances the elimination of xenobiotics [2]. In clinical oncology, P-gp is a major driver of multidrug resistance, as it actively removes various chemotherapeutic agents from cancer cells, thereby reducing their efficacy [1, 3]. Beyond cancer, P-gp is a central mediator of drug-drug and herb-drug interactions; for instance, constituents in herbal extracts like St. John's Wort can induce P-gp expression, leading to sub-therapeutic levels of co-administered drugs like digoxin or cyclosporine [4]. Conversely, many phytochemicals such as quercetin or curcumin can inhibit P-gp, potentially increasing the systemic exposure and toxicity of its substrates [4]. Understanding the aggregate effect of these constituents is vital for predicting the pharmacokinetic profile of complex botanical products [3, 4]. Sources: [1] UniProt P08183; [2] NCBI Gene 5243; [3] FDA Drug Interaction Guidelines; [4] PMID: 23116313.

Other names
P-glycoprotein 1P-gpMDR1ATP-binding cassette sub-family B member 1CD243
02

Mechanism of action

ATP-dependent efflux pump that transports a wide variety of hydrophobic substrates across cell membranes against a concentration gradient [1, 2].

03

Biological functions

Xenobiotic transportDrug effluxBlood-brain barrier maintenanceIntestinal absorption regulationBiliary excretionRenal excretion
04

Disease associations

Cancer (Multidrug resistance)Drug-resistant epilepsyInflammatory bowel diseaseAlzheimer's disease
05

Safety considerations

Drug-drug interactionsHerb-drug interactionsIncreased CNS toxicity of substrates upon inhibitionReduced oral bioavailability of substrates upon induction
06

Interacting drugs

Verapamil

10 more in the full profile.

07

Biomarkers

ABCB1 mRNA expression levelsP-glycoprotein protein expression (IHC)Rhodamine 123 efflux activityABCB1 C3435T polymorphism

Beyond the preview

Go deeper on Multidrug resistance protein 1 (P-glycoprotein) (ABCB1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Multidrug resistance protein 1 (P-glycoprotein) (ABCB1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call